tert-Butyl (2-oxopiperidin-3-yl)carbamate, 95.0%, 1g

4,7,10,13-Tetraoxa-16-azaoctadecanoic acid, 18-bromo-17-oxo-, 2,5-dioxo-1-pyrrolidinyl ester, 95%, 1g

1,3-Butanediol, min. 99%, for synthesis, 25 l, plastic packaging.

2-Bromo-4-methylpentanoic acid, 95.0%, 1g

3-(4-fluoro-3-methoxyphenyl)-5-methyl-4,5-dihydro-1,2-oxazole-5-carboxylic acid, 95.0%, 1g

Capsazepine, >99%, 5mg

2-Bromo-6-fluoro-4-methylpyridine, 95.0%, 5g

3-Ethylisonicotinonitrile, 95.0%, 250mg

1,6-Diaminohexane, 98.0%, 250g

(1S)-2,2,2-TRIFLUORO-1-NAPHTHYLETHYLAMINE, 95.0%, 250mg

tert-Butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate, 98%, 25g

Diethyl-(2-nitro-4-trifluoromethyl-phenyl)-amine, 5g

1-Ethyl-6-methoxy-1,2,3,4-tetrahydroquinoline, 97.0%, 250mg